Enlaza Therapeutics raised $100 million to develop permanently binding antibody-drug conjugates for cancer with a goal of bringing them into the first-ever human studies.
The company announced Tuesday that the Series A round was led by JP Morgan’s Life Sciences Private Capital, which was formed in late 2022 to invest in early-stage biotech companies. Enlaza is the firm’s first disclosed investment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.